Skip to main contentrtttttt Skip to main content
Integrative Psychiatry

Music to My Ears: A Place for Music in Psychiatry

Even without words, music speaks to us. As the psychiatrist Dr. Rakesh Jain says, “Music is our first language.” Yes, there has been research conducted on music for many decades, but we know that music touches us because we feel it, we respond to it. Our brains become activated, chemicals are released, and our nervous system is altered when we listen to music that moves us.

Musical Moods

The power of music isn’t neutral; it can shift us into different moods depending on both the compositional structure and our own personal associations with a particular song. In some models, musical moods are produced by different combinations of rhythm, pitch, intensity, and timbre. While rhythm is the arrangement of sounds including beat, melody, and pauses, pitch is the frequency of the music, categorized on a scale from high to low. Intensity is defined as the loudness of the composition; finally, timbre is the perceived “color” of the music that arises from using different instruments or voices, even if the note or pitch of the music is the same.

However, the mood that a song conveys is not necessarily generalizable; for example, what sounds sad to me might sound calming to you. As humans, we project our own state of mind onto the music that is produced, and we may have certain memories that are recalled when listening to certain songs. Yet this can be an advantage of using music for the benefits of mental health. It is also why developing personal playlists is often more emotionally evocative than listening to those premade by others.

Therapeutic Uses of Music

Music processing uses the same brain areas that are active during the processing of emotion, pain, and wellbeing. Therefore, our brains show altered activity levels that reflect the different emotions evoked by music. These changes in brain activity and mood correspond to changes in release of neurotransmitters and hormones that alter sensations of pleasure, pain, and social bonding. So how might we use musical biohacking in psychiatry? 

Music for Emotional Congruence: Choosing music that matches a person’s mood can support the individual in identifying, feeling, and working through emotions, from grief to anger to excitement. In this way, music may be used as a mindfulness practice; however, it is important to caution against perseverating in any emotional state for too long.

Music for Treatment Interventions: Because music influences emotional valence, music therapy is a wonderful addition to psychotherapy in the treatment of depression, anxiety, and posttraumatic stress disorder. Choosing music that stimulates joy or peace can help stimulate different areas of the brain and aid in shifting a person’s present moment perspective.

Music for Attention and Cognition: There have been many studies that have identified the usefulness of both listening to music and learning to play music on cognitive function across the lifespan. When applied in appropriate contexts, music interventions can enhance working memory, cognitive flexibility, creativity, and concentration. In addition, music that is perceived to the listener as pleasant can reduce sensations of pain.

Music for Social Connection: Given its emotional nature, music is a universal tool for communicating on a deeper level with others, sharing identity, personality, and emotive interrelatedness. Music can even support early attachments in pregnancy and labor by increasing oxytocin and reducing anxiety in mothers.

Conclusion

Music transcends verbal communication, moving us emotionally, physiologically, and spiritually. Its ability to influence our mood, evoke memories, and alter brain activity makes it a powerful tool in both personal and therapeutic settings. Music is a vital component of both individual and communal health, and it feels only natural that its integration into therapeutic practices will improve outcomes. Indeed, music’s language can impact lives in ways that words alone cannot.

Sara Reed, MS, LMFT

Sara Reed is a Licensed Marriage and Family Therapist and CEO of Mind’s iHealth Solutions, a digital health company that provides evidence based and culturally responsible mental health services for underserved groups. As a mental health futurist and clinical researcher, Sara examines the ways culture informs the way we diagnose and treat mental illness. Sara’s prior research work includes participation as a study therapist in psychedelic therapy research at Yale University and the University of Connecticut’s Health Center. Sara was the first Black therapist to provide MDMA-assisted psychotherapy in a clinical trial and continues to engage in ongoing advocacy work around health equity in psychedelic medicine.

https://psychiatryinstitute.com/wp-content/uploads/2019/11/Jeffrey-Guss.png

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy and the treatment of substance use disorders. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psychedelic-assisted psychotherapy in the treatment of cancer-related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psychedelic-Assisted therapy in the treatment of Alcoholism, a collaborator with Yale University’s study on psychedelic-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS (Multidisciplinary Association for Psychedelic Studies) study on treatment of Post Traumatic Stress Disorder with Psychedelic-Assisted Psychotherapy. 

Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He has published (with Elizabeth Nielson, PhD) a paper on “the influence of therapists’ first had experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training” in The Journal of Psychedelic Studies, August, 2018. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies and Supervisor in NYU’s Fellowship in Addiction Psychiatry. 

Dr. Guss maintains a private practice in New York City.

Will Van Derveer, MD

Will Van Derveer, MD is Co-Founder of Integrative Psychiatry Institute and Integrative Psychiatry Centers. Dr. Van Derveer was co-investigator on a phase 2 MAPS study of Psychedelic-assisted psychotherapy for treatment-resistant PTSD, and co-authored the publication of this study in 2018. He has also provided Psychedelic-assisted psychotherapy in two MAPS training studies. An active provider of KAP at his clinic in Boulder, CO, he has been teaching others KAP therapy for several years. Dr. Van Derveer contributed a chapter on mescaline in the 2021 "Handbook of Medical Hallucinogens" (edited by Charles Grob and Jim Grigsby). He is co-host of the Higher Practice Podcast.

Dr. Van Derveer regards unresolved emotional trauma as the most significant under-recognized root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass.


Scott has been a student of consciousness since his honors thesis on that topic at the University of Arizona in the 1970s under the tutelage of Dr. Andrew Weil. Following medical school, Scott studied Jungian therapy and acupuncture while working as a primary care physician in a rural area for four years. Psychedelic-assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a psychiatry residency at Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico.

In 2010 he founded Wholeness Center in Fort Collins. This innovative clinic provides cross-disciplinary evaluation and care for all mental health concerns. Scott serves as a site Principal Investigator and therapist for the Phase III trial of psychedelic-assisted psychotherapy for PTSD sponsored by (MAPS). He has also published numerous articles about his research on (CBD) in mental health. Currently, Scott works extensively with psychedelic-assisted-psychotherapy. He lectures all over the world to professional groups interested in a deeper look at mental health issues, safer tools, and a paradigm-shifting perspective about transformative care.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.